These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 29766510

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
    Andringa G, van Oosten RV, Unger W, Hafmans TG, Veening J, Stoof JC, Cools AR.
    Eur J Neurosci; 2000 Aug; 12(8):3033-43. PubMed ID: 10971644
    [Abstract] [Full Text] [Related]

  • 4. The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.
    Jamali-Raeufy N, Mojarrab Z, Baluchnejadmojarad T, Roghani M, Fahanik-Babaei J, Goudarzi M.
    Metab Brain Dis; 2020 Mar; 35(3):539-548. PubMed ID: 32016817
    [Abstract] [Full Text] [Related]

  • 5. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
    Inden M, Kitamura Y, Kondo J, Hayashi K, Yanagida T, Takata K, Tsuchiya D, Yanagisawa D, Nishimura K, Taniguchi T, Shimohama S, Sugimoto H, Akaike A.
    J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
    Xue YQ, Zhao LR, Guo WP, Duan WM.
    Neuroscience; 2007 May 25; 146(3):1245-58. PubMed ID: 17363174
    [Abstract] [Full Text] [Related]

  • 10. Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease.
    Du XX, Xu HM, Jiang H, Song N, Wang J, Xie JX.
    Neurosci Bull; 2012 Jun 25; 28(3):253-8. PubMed ID: 22622825
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S, Rentsch P, Li KM, Vissel B.
    PLoS One; 2015 Jun 25; 10(4):e0124325. PubMed ID: 25902062
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.
    Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton PS.
    Neuropeptides; 2012 Oct 25; 46(5):183-93. PubMed ID: 22921965
    [Abstract] [Full Text] [Related]

  • 17. [The protective effect of ginsenoside Rg1 on dopaminergic neurons of substantia in the ovariectomized rat model of Parkinson's disease].
    Xu L, Liu LX, Chen WF, Xie JX, Huang WX.
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2008 Feb 25; 24(1):1-5. PubMed ID: 21141541
    [Abstract] [Full Text] [Related]

  • 18. The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease.
    Yu H, Liu X, Chen B, Vickstrom CR, Friedman V, Kelly TJ, Bai X, Zhao L, Hillard CJ, Liu QS.
    Cells; 2021 Dec 16; 10(12):. PubMed ID: 34944056
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.